melatonin has been researched along with Thrombopenia in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aging and advanced cancer are characterized by similar neuroendocrine and immune deficiencies; the most important of them consist of diminished nocturnal production of the pineal hormone melatonin (MLT) and decreased production of IL-2." | 9.16 | Cancer as the main aging factor for humans: the fundamental role of 5-methoxy-tryptamine in reversal of cancer-induced aging processes in metabolic and immune reactions by non-melatonin pineal hormones. ( Lissoni, P; Messina, G; Rovelli, F, 2012) |
| " The study was performed in 14 metastatic breast cancer women treated by weekly epirubicin." | 9.09 | Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study. ( Ardizzoia, A; Barni, S; Giani, L; Lissoni, P; Malugani, F; Mandalà, M; Paolorossi, F; Tancini, G, 1999) |
| " In particular, thrombopoiesis has been proven to be stimulated by melatonin, and the pineal indole has been shown to be effective in the treatment of thrombocytopenia resulting from different causes." | 9.09 | Thrombopoietic properties of 5-methoxytryptamine plus melatonin versus melatonin alone in the treatment of cancer-related thrombocytopenia. ( Bonfanti, A; Bucovec, R; Fumagalli, L; Giani, L; Lissoni, P; Mandelli, A; Roselli, MG; Rovelli, F, 2001) |
| "Melatonin does not affect DIC but diminishes thrombocytopenia and haemolysis during endotoxaemia." | 7.83 | Melatonin does not affect disseminated intravascular coagulation but diminishes decreases in platelet count during subacute endotoxaemia in rats. ( de Groot, H; Effenberger-Neidnicht, K; Görlinger, K; Hartmann, M; Lansink, MO, 2016) |
| "Thrombocytopenia is a frequent haematologic complication of IL-2 immunotherapy of cancer." | 5.29 | Prevention of interleukin-2-induced thrombocytopenia during the immunotherapy of cancer by a concomitant administration of the pineal hormone melatonin. ( Barni, S; Bregani, ER; Brivio, F; Conti, A; Lissoni, P; Maestroni, GJ; Rossini, F; Tancini, G, 1995) |
| "Aging and advanced cancer are characterized by similar neuroendocrine and immune deficiencies; the most important of them consist of diminished nocturnal production of the pineal hormone melatonin (MLT) and decreased production of IL-2." | 5.16 | Cancer as the main aging factor for humans: the fundamental role of 5-methoxy-tryptamine in reversal of cancer-induced aging processes in metabolic and immune reactions by non-melatonin pineal hormones. ( Lissoni, P; Messina, G; Rovelli, F, 2012) |
| " The study was performed in 14 metastatic breast cancer women treated by weekly epirubicin." | 5.09 | Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study. ( Ardizzoia, A; Barni, S; Giani, L; Lissoni, P; Malugani, F; Mandalà, M; Paolorossi, F; Tancini, G, 1999) |
| " In particular, thrombopoiesis has been proven to be stimulated by melatonin, and the pineal indole has been shown to be effective in the treatment of thrombocytopenia resulting from different causes." | 5.09 | Thrombopoietic properties of 5-methoxytryptamine plus melatonin versus melatonin alone in the treatment of cancer-related thrombocytopenia. ( Bonfanti, A; Bucovec, R; Fumagalli, L; Giani, L; Lissoni, P; Mandelli, A; Roselli, MG; Rovelli, F, 2001) |
| "Clinical studies have shown that melatonin lowers the frequency of thrombocytopenia in patients with cancer undergoing radiotherapy or chemotherapy." | 3.96 | Melatonin protects against apoptosis of megakaryocytic cells via its receptors and the AKT/mitochondrial/caspase pathway. ( Chen, C; Chen, S; Chen, Y; He, Y; Li, L; Li, S; Wang, B; Xin, H; Xu, X; Yang, L; Yang, M; Ye, J; Zhang, C; Zhang, Q, 2020) |
| "Melatonin does not affect DIC but diminishes thrombocytopenia and haemolysis during endotoxaemia." | 3.83 | Melatonin does not affect disseminated intravascular coagulation but diminishes decreases in platelet count during subacute endotoxaemia in rats. ( de Groot, H; Effenberger-Neidnicht, K; Görlinger, K; Hartmann, M; Lansink, MO, 2016) |
| "Thrombocytopenia is a frequent haematologic complication of IL-2 immunotherapy of cancer." | 1.29 | Prevention of interleukin-2-induced thrombocytopenia during the immunotherapy of cancer by a concomitant administration of the pineal hormone melatonin. ( Barni, S; Bregani, ER; Brivio, F; Conti, A; Lissoni, P; Maestroni, GJ; Rossini, F; Tancini, G, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, M | 1 |
| Li, L | 1 |
| Chen, S | 1 |
| Li, S | 1 |
| Wang, B | 1 |
| Zhang, C | 1 |
| Chen, Y | 1 |
| Yang, L | 1 |
| Xin, H | 1 |
| Chen, C | 1 |
| Xu, X | 1 |
| Zhang, Q | 1 |
| He, Y | 1 |
| Ye, J | 1 |
| Lissoni, P | 5 |
| Messina, G | 1 |
| Rovelli, F | 2 |
| Lansink, MO | 1 |
| Görlinger, K | 1 |
| Hartmann, M | 1 |
| de Groot, H | 1 |
| Effenberger-Neidnicht, K | 1 |
| Bregani, ER | 1 |
| Rossini, F | 2 |
| Barni, S | 3 |
| Tancini, G | 3 |
| Brivio, F | 1 |
| Conti, A | 1 |
| Maestroni, GJ | 1 |
| Paolorossi, F | 2 |
| Maffé, P | 1 |
| Di Bella, L | 1 |
| Mandalà, M | 1 |
| Ardizzoia, A | 1 |
| Malugani, F | 1 |
| Giani, L | 2 |
| Bucovec, R | 1 |
| Bonfanti, A | 1 |
| Mandelli, A | 1 |
| Roselli, MG | 1 |
| Fumagalli, L | 1 |
4 trials available for melatonin and Thrombopenia
| Article | Year |
|---|---|
Cancer as the main aging factor for humans: the fundamental role of 5-methoxy-tryptamine in reversal of cancer-induced aging processes in metabolic and immune reactions by non-melatonin pineal hormones.
Topics: 5-Methoxytryptamine; Administration, Oral; Age Factors; Aging; Antineoplastic Combined Chemotherapy | 2012 |
The pineal hormone melatonin in hematology and its potential efficacy in the treatment of thrombocytopenia.
Topics: Adolescent; Adult; Aged; Female; Hematopoiesis; Humans; Male; Melatonin; Middle Aged; Platelet Count | 1996 |
Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Breast Neoplasms | 1999 |
Thrombopoietic properties of 5-methoxytryptamine plus melatonin versus melatonin alone in the treatment of cancer-related thrombocytopenia.
Topics: 5-Methoxytryptamine; Adult; Aged; Blood Platelets; Drug Therapy, Combination; Female; Hematopoiesis; | 2001 |
3 other studies available for melatonin and Thrombopenia
| Article | Year |
|---|---|
Melatonin protects against apoptosis of megakaryocytic cells via its receptors and the AKT/mitochondrial/caspase pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blood Platelets; Bone Marrow; Caspases; Cell Line, Tumor; | 2020 |
Melatonin does not affect disseminated intravascular coagulation but diminishes decreases in platelet count during subacute endotoxaemia in rats.
Topics: Animals; Blood Platelets; Blood Pressure; Disseminated Intravascular Coagulation; Endotoxemia; Hemol | 2016 |
Prevention of interleukin-2-induced thrombocytopenia during the immunotherapy of cancer by a concomitant administration of the pineal hormone melatonin.
Topics: Adult; Aged; Blood Platelets; Drug Therapy, Combination; Female; Humans; Interleukin-2; Interleukin- | 1995 |